Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review

Author(s): Angela Rampa*, Silvia Gobbi, Rita Maria Concetta Di Martino, Federica Belluti, Alessandra Bisi*

Journal Name: Current Topics in Medicinal Chemistry

Volume 17 , Issue 31 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


In industrialized countries, Alzheimer's disease represents the most devastating neurodegenerative disorder in elderly people and the search for a disease modifying agent is still justified by this unmet need. Several possible targets have been explored to find an appropriate drug therapy, and in this review, dual inhibitors of beta secretase and glycogen synthase kinase 3, recently reported in literature, will be appraised. Applying a ligand-based approach, the triazinone core emerged as a suitable scaffold to simultaneously bind the aspartic dyad of BACE-1 and the ATP site of GSK-3β, leading to a series of small molecules endowed with a balanced micromolar affinity and a promising pharmacokinetic profile.

Differently, by means of a structure-based approach, a series of well-balanced dual binding molecules were designed, taking advantage of the versatility of the curcumin scaffold. For some of these new compounds a potential neuroprotective effect was also observed, due to their ability to counteract the oxidative stress through the inhibition of NQO1 enzyme.

Finally, different virtual screening analyses were performed, leading to the identification of new potential scaffolds deserving further development.

Keywords: Dual BACE-1/GSK-3β, Alzheimer, Neurodegenerative Diseases (ND), Precursor protein, Neurofibrillary tangles (NFTs), NQO1 enzyme.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [3361 - 3369]
Pages: 9
DOI: 10.2174/1568026618666180112161406
Price: $65

Article Metrics

PDF: 51